Drug Search Results
More Filters [+]

WHG-626

Alternative Names: WHG-626, WHG626
Latest Update: 2024-03-15
Latest Update Note: Clinical Trial Update

Product Description

Novartis is developing WHG-626, an oral treatment for patients with Multiple Myeloma. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04123418)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for WHG-626

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title